About CJC + Ipa Store: An Independent Almanac of the CJC-1295 Ipamorelin Literature

What This Site Is

CJC + Ipa Store is a curated archive — an indexed almanac of the peer-reviewed research on CJC-1295 ipamorelin, a two-component growth hormone secretagogue blend studied in human, rodent, and multi-species models across more than two decades of endocrinology. It keeps no exam room and no clinical staff; no one here diagnoses, prescribes, or offers medical direction. It manufactures nothing and fills no orders — the holdings are studies, and the studies are all that is kept.

The "store" in the domain name is an archival reference: the holdings of a curated library, sorted like a folk-art almanac. This site does not sell, fulfill, or process orders for any compound. It is an indexed reading room for the 22 numbered findings and 4 recent-studies entries in the CJC-1295 ipamorelin peer-reviewed record.

The "clinic," "doctor," "store," and "rx" modifiers that recur across the portfolio's domain names are positional references — they describe a site's stance toward the literature (a clinic's diagnostic depth, a doctor's explanatory register, an archivist's curated shelf), not the services on offer. No healthcare services, clinical consultations, or prescriptions are provided here or anywhere on this domain.

Editorial Methodology

Every quantitative claim on this site is sourced to a numbered citation in the References index. Citations are drawn from PubMed-indexed journals, ClinicalTrials.gov, and peer-reviewed pharmacology and endocrinology literature. The record spans 1998 (Raun et al., the ipamorelin selectivity paper) through 2025 (the tesamorelin meta-analysis). Every claim is attributed to the species and study design in which it was measured.

This archive does not cite preprints, promotional literature, manufacturer white papers, or community anecdotes. Where the peer-reviewed base is thin — published human half-life data for ipamorelin, for instance — the gap is stated outright. Where findings come from animal models, the species and model are named. The catalogue is a record of what controlled studies measured, not a protocol for anyone to follow.

Regulatory Status of CJC-1295 and Ipamorelin

Neither CJC-1295 nor ipamorelin holds FDA approval for any human indication. CJC-1295 (with DAC) reached Phase I/II-context human studies published in 2006–2009 through ConjuChem Inc. Ipamorelin was studied in Phase I/II for postoperative ileus (NCT00672074, Rhythm Pharmaceuticals/Helsinn) and in a small Phase I safety study. Neither compound has completed Phase III trials.

Both compounds appear on the WADA Prohibited List: CJC-1295 as a GHRH analog (Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics) and ipamorelin as a growth hormone secretagogue (GHS-R1a agonist, Section S2). Both may additionally fall under Section S0 Non-Approved Substances.

As of December 2024 FDA Pharmacy Compounding Advisory Committee briefing documents, CJC-1295 acetate forms were proposed not to be included on the 503A Bulks List for compounding under section 503A of the FD&C Act. Ipamorelin's compounding status is under ongoing evaluation.

Is CJC-1295/ipamorelin FDA-approved? No. Who is a candidate for CJC-1295 and ipamorelin research protocols? Published Phase I/II trials enrolled healthy adults aged 21–60 with normal pituitary function, no active malignancy, no diabetes, and no pregnancy. These subject selection criteria are research-protocol parameters; they do not constitute eligibility guidance for any non-research use.

Editorial Disclaimer

This archive is a reading of peer-reviewed scientific literature. It is not a source of medical advice, clinical guidance, or treatment recommendation. Nothing on the site should be read as endorsing the acquisition, preparation, or administration of any compound. For any medical concern, consult a qualified healthcare professional.

The register throughout describes findings in the species and contexts in which they were measured: rodent findings stay attributed to rodent models, human findings to their trial populations. No finding is stretched into a personal recommendation.